title: Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma.
abstract: AIM, PATIENTS & METHODS: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014.
  
  
  RESULTS
  In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥ 4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio <3 was associated both with OS and progression-free survival (50.4 vs 8.4 and 20.0 vs 3.3 months).
  
  
  CONCLUSIONS
  Sunitinib is active and feasible. Patients receiving <4 full-dose cycles or having increased neutrophil-lymphocyte ratio achieved worse outcomes: therefore, these are present potential predictive factors.
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Maruzzo
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Basso
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Diminutto
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Roma
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Fable
authors.initials: F
authors.lastname: Zustovich
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Brunello
authors.affiliation: Clinical Trials & Biostatistic Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Fiduccia
authors.affiliation: Cardiology Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Banzato
authors.affiliation: Urology Section, Department of Surgical, Oncological & Gastroenterological Sciences, University of Padova, Italy.
authors.forename: Filiberto
authors.initials: F
authors.lastname: Zattoni
authors.affiliation: Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
authors.forename: Vittorina
authors.initials: V
authors.lastname: Zagonel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007249:Inflammation / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
keywords: dose exposure; neutrophil–lymphocite ratio; real world; renal cell carcinoma; sunitinib; survival